MA-WHOOP
29.4.2024 20:11:30 CEST | Business Wire | Press release
WHOOP, the human performance company, today announced the expansion of its global footprint, now shipping to 56 markets worldwide, with more launches ahead. Additionally, the WHOOP app is now available in Italian and Spanish (Latin America), as well as English, French, and German. To support continued growth and momentum, WHOOP named new leaders to its C-suite to deliver on the WHOOP mission of helping people achieve their goals, by providing best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, strain, and health. To help everyone start their journey, WHOOP is currently offering a one-month free trial that can be accessed on WHOOP.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429085870/en/
WHOOP announces significant global expansion, appoints new senior leadership. Continues "Free Trials," making it the only wearable to offer "Try Before You Buy." (Photo: Business Wire)
WHOOP Global Expansion
With a commitment to serving its global community to unlock their potential, WHOOP has expanded its reach to several key markets and regions, where there’s been rising consumer demand for and adoption of the brand. Consumers in Qatar, Saudi Arabia, Kuwait, Bahrain, Hong Kong, Israel, Korea, and Taiwan can now purchase WHOOP directly and the brand will ship to each of these markets, creating a seamless experience for its members.
The Gulf is a key region for the brand’s growth. In fact, their digital health market is expected to witness healthy, double-digit growth by 2027, according to Medi-Tech Insights. As a world class health and performance monitor, WHOOP provides coaching to improve overall well-being and foster behavior change.
To support global expansion, the WHOOP app is now available in Italian and Latin American Spanish to complement its existing languages: English, French and German, with additional language rollouts to come. This expansion ensures that WHOOP members worldwide can access the full suite of content and features in their native language.
“WHOOP is experiencing remarkable growth and momentum, particularly in new markets around the world. We’re excited to open these new markets and provide over 125 million people with access to WHOOP,” said Will Ahmed, Founder and CEO of WHOOP. “This market growth and the launch of Spanish and Italian in the WHOOP app is just the start of our international expansion. Our teams, including those led by three of our newest C-suite leaders, are working every day to unlock new markets and help introduce new members to the power of our WHOOP membership.”
New Executive Leadership at WHOOP
To spearhead continued growth and global expansion, WHOOP has appointed new leaders to its executive team:
- Ed Baker joins WHOOP as Chief Growth Officer, following the acquisition of Baker's previous company, AnyQuestion. Before that, Baker led growth teams at Facebook and Uber during periods of extraordinary growth. He has also served on the WHOOP Board of Directors for nearly five years. Baker will lead efforts to fuel the next phase of hyper-growth at WHOOP.
- Michener Chandlee is now Chief Financial Officer at WHOOP, leveraging his extensive financial expertise to drive strategic financial planning and operational excellence. Prior to WHOOP, Chandlee was the CFO of Fanatics and also spent nearly 20 years at Nike in various leadership roles, including Chief Risk Officer and CFO of Nike’s Global Marketplace.
- John Sullivan has been promoted to Chief Marketing Officer, bringing his wealth of experience in marketing strategy and brand development to further elevate the presence of WHOOP in the global marketplace. Sullivan has worked at WHOOP for more than seven years during which he’s developed the direct-to-consumer business at WHOOP, overseeing all marketing functions of Brand, Commercial, Lifecycle, Business Development and Accessories and Apparel. Prior to WHOOP, he held positions in marketing at Tracksmith, Puma and Monitor Group, a strategy consulting firm.
To learn more and discover how WHOOP helps its members unlock their performance, go to www.whoop.com. To make it even more convenient than ever before to access WHOOP, it is available for purchase on Amazon.com, as well as at Best Buy and Dick’s Sporting Goods.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429085870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom